MetaCap

Aspen Neuroscience (ASPE) vs Avalo Therapeutics (AVTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avalo Therapeutics is the larger company by market cap ($390.9 million vs $361.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASPE-16.59%AVTX-5.72%
+21%-1%-23%
Oct 30, 20261 yearNov 20, 2026
ASPE-16.59%AVTX-5.72%
+9%-4%-18%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASPE versus AVTX key metrics
MetricASPEAVTX
Share price$12.42$6.76
Market cap$361.16M$390.88M
1-day change+0.24%+0.15%
YTD return—-62.78%
1-year return—-62.09%
5-year return—-99.89%
EPS (TTM)$-4.89$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$59.00K
Revenue growth (YoY)—-86.62%
Net income (latest FY)—$-78.26M
Operating margin—-123601.69%
Net margin—-132642.37%
52-week high$14.90$24.27
52-week low$11.20$6.53
Distance from 52-week high-16.64%-72.15%
Analyst consensus—strong_buy
Avg. price target upside—+414.79%
Average volume352.42K1.80M
Shares outstanding29.08M57.82M
Employees12033
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aspen Neuroscience

ASPE stock →

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Avalo Therapeutics

AVTX stock →

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

ASPE vs AVTX FAQ

Which is bigger, Aspen Neuroscience or Avalo Therapeutics?

Avalo Therapeutics (AVTX) is larger, with a market capitalization of $390.88M compared with $361.16M for Aspen Neuroscience (ASPE).

Are Aspen Neuroscience and Avalo Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons